+357 96 030922
info@marketpublishers.com

Global Artemisinin Market Size study, by Malaria Type (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Malariae, Plasmodium Knowlesi), Product (Injections, Tablets), Type (Combination, Monotherapy) and Regional Forecasts 2022-2032

https://marketpublishers.com/r/G99CFCBAEB38EN.html
Date: May 2025
Pages: 285
Price: US$ 3,218.00 (Single User License)
ID: G99CFCBAEB38EN

Abstracts

Global Artemisinin Market is valued approximately at USD 0.67 billion in 2023 and is anticipated to grow with a steady CAGR of more than 4.2% over the forecast period 2024–2032. Artemisinin, a naturally derived antimalarial compound sourced from the Artemisia annua plant, has emerged as the cornerstone of modern malaria therapy. Its potent efficacy, particularly against drug-resistant strains of Plasmodium falciparum, has led to widespread adoption across both monotherapy and combination treatments. As malaria continues to pose a major health burden, especially across tropical and subtropical regions, the strategic role of artemisinin-based therapies remains paramount in global health initiatives aiming to curb and eliminate the disease.

The market's momentum is being accelerated by growing malaria prevalence in sub-Saharan Africa and parts of Southeast Asia, prompting increased government procurement of artemisinin-based combination therapies (ACTs). With international agencies like WHO and Global Fund supporting subsidized treatment access and stockpile reserves, the commercial production of artemisinin and its derivatives has scaled substantially. Meanwhile, pharmaceutical manufacturers are developing novel formulations—such as artemisinin-piperaquine fixed-dose combinations and long-acting injectables—to enhance compliance and therapeutic impact. Further, growing awareness of plant-based APIs and integrated vector control programs are expected to complement the demand trajectory through 2032.

+357 96 030922
info@marketpublishers.com

Nevertheless, challenges persist that could restrain the market from achieving its full potential. The volatility in artemisinin raw material pricing—due to weather-dependent cultivation—poses a supply chain risk. Additionally, emerging resistance to ACTs in parts of Southeast Asia and Oceania threatens to undermine treatment efficacy, urging a need for next-gen derivatives and resistance-monitoring systems. Furthermore, limited production infrastructure in low-income countries and quality compliance issues remain areas that necessitate regulatory and logistical interventions. However, biotechnological breakthroughs in semi-synthetic artemisinin synthesis and expanding research into artemisinin-based cancer and anti-inflammatory therapies offer promising avenues for diversification and market expansion.

Technological advancements are redefining artemisinin manufacturing through synthetic biology approaches and fermentation-based methods, which aim to stabilize supply chains and reduce ecological dependency. Simultaneously, the growing trend of public-private partnerships, especially between global health bodies and pharma producers, is fostering innovation and ensuring equitable access. The rise of e-pharmacies and digitized distribution networks has further strengthened last-mile delivery of malaria treatments in remote areas, paving the way for enhanced market penetration and real-time stock monitoring.

Regionally, the Asia Pacific market dominates the artemisinin industry, led by high malaria-endemic zones and a strong production base in China and Vietnam. Africa follows closely, driven by large-scale donor-funded healthcare campaigns and a rising commitment from national health ministries. Latin America is showing a steady uptake, supported by WHO’s malaria elimination roadmap in the region. Meanwhile, North America and Europe, though low in malaria burden, are contributing to the market via research grants, vaccine integration trials, and export of pharmaceutical-grade artemisinin derivatives.

Major market player included in this report are:

Guilin Pharmaceutical Co., Ltd.

Sanofi S.A.

Novartis AG

Cipla Limited

+357 96 030922
info@marketpublishers.com

IPCA Laboratories Ltd.

Zhenhua Pharma Co., Ltd.

Artecef B.V.

KPC Pharmaceuticals, Inc.

Calyx Chemicals and Pharmaceuticals Ltd.

Shanghai Natural Bio-engineering Co., Ltd.

Zhifei Biological Products Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Zhejiang Holley Pharmaceutical Co., Ltd.

Guangdong New South Group Co., Ltd.

Ajanta Pharma Ltd.

The detailed segments and sub-segment of the market are explained below:

By Malaria Type

Plasmodium Falciparum

Plasmodium Vivax

Plasmodium Ovale

Plasmodium Malariae

Plasmodium Knowlesi

+357 96 030922
info@marketpublishers.com

By Product

- Injections
- Tablets

By Type

- Combination
- Monotherapy

By Region:

North America

- U.S.
- Canada

Europe

- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe

Asia Pacific

+357 96 030922
info@marketpublishers.com

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

+357 96 030922
info@marketpublishers.com

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Companies Mentioned

Guilin Pharmaceutical Co., Ltd.

Sanofi S.A.

Novartis AG

Cipla Limited

IPCA Laboratories Ltd.

Zhenhua Pharma Co., Ltd.

Artecef B.V.

KPC Pharmaceuticals, Inc.

Calyx Chemicals and Pharmaceuticals Ltd.

+357 96 030922
info@marketpublishers.com

Shanghai Natural Bio-engineering Co., Ltd.

Zhifei Biological Products Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Zhejiang Holley Pharmaceutical Co., Ltd.

Guangdong New South Group Co., Ltd.

Ajanta Pharma Ltd.

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

CHAPTER 4. GLOBAL ARTEMISININ MARKET INDUSTRY ANALYSIS

CHAPTER 5. GLOBAL ARTEMISININ MARKET SIZE & FORECASTS BY MALARIA TYPE, 2022–2032

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

CHAPTER 9. COMPETITIVE INTELLIGENCE

CHAPTER 10. RESEARCH PROCESS

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Artemisinin Market Size study, by Malaria Type (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Malariae, Plasmodium Knowlesi), Product (Injections, Tablets), Type (Combination, Monotherapy) and Regional Forecasts 2022-2032

Product link: https://marketpublishers.com/r/G99CFCBAEB38EN.html

Price: US$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G99CFCBAEB38EN.html